Filing Details

Accession Number:
0001104659-24-004540
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-17 17:16:56
Reporting Period:
2024-01-13
Accepted Time:
2024-01-17 17:16:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1442836 Mersana Therapeutics Inc. MRSN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1991787 Mohan Bala C/O Mersana Therapeutics, Inc.
840 Memorial Drive
Cambridge MA 02139
Svp, Chief Development Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-13 8,750 $0.00 17,483 No 4 M Direct
Common Stock Disposition 2024-01-16 3,431 $2.71 14,052 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Disposition 2024-01-13 8,750 $0.00 8,750 $0.00
Common Stock Stock Option (Right to Buy) Acquisiton 2024-01-15 262,500 $0.00 262,500 $3.02
Common Stock Restricted Stock Unit Acquisiton 2024-01-15 58,333 $0.00 58,333 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
26,250 No 4 M Direct
262,500 2034-01-14 No 4 A Direct
58,333 No 4 A Direct
Footnotes
  1. Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 13, 2023.
  2. Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
  3. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.70 to $2.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. Each RSU represents the contingent right to receive one share of common stock of the Issuer.
  5. 25% of the total number of RSUs granted vested on January 13, 2024, and the remainder shall vest thereafter in equal annual installments over the next three years.
  6. The option shall vest in equal quarterly installments over four years from the date of grant.
  7. The RSUs shall vest in equal annual installments over four years from the date of grant.